Methods of preparation of multifunctional microbubbles and their in vitro / In vivo assessment of stability, functional and structural properties

Current Pharmaceutical Design

Volumn 18, Issue 15, 2012, Pages 2135-2151

  Cavalieri, Francesca ^a,b,c   Zhou, Meifang ^a   Tortora, Mariarosaria ^c   Lucilla, Baldassarri ^d   Ashokkumar, Muthupandian ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b IRCCS NEUROMED   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Blood brain barrier; Drug delivery; Microbial films; Microbubbles; Nanoparticles; Ultrasound

Indexed keywords

BOVINE SERUM ALBUMIN; DOXORUBICIN; GOLD NANOPARTICLE; HEMOGLOBIN; HUMAN SERUM ALBUMIN; IRON OXIDE; LYSOZYME; NANOBUBBLE; NANOPARTICLE; NANOROD; OPSONIN; PERFLUOROPENTANE; POLYMER; POLYMETHACRYLIC ACID; QUANTUM DOT; SILICON DIOXIDE;

BETA SHEET; BIOFILM; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; GENE THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROBUBBLE; MICROFLUIDICS; MOLECULAR IMAGING; MOLECULAR SIZE; NANOANALYSIS; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; STAPHYLOCOCCUS AUREUS;

ACOUSTICS; ANIMALS; BLOOD-BRAIN BARRIER; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; LIPIDS; MICROBUBBLES; POLYMERS; PROTEINS; THROMBOLYTIC THERAPY; ULTRASONOGRAPHY;

EID: 84860147788     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800099874     Document Type: Review

References (105)

1. Sirsi S, Borden M. Microbubble compositions, properties and bio- medical applications. Bubble Sci Eng Technol 2009; 1: 3-17.
2. Postema M, Schmitz G. Bubble dynamics involved in ultrasonic imaging. Expert Rev Mol Diagn 2006; 6: 493-502.
3. Cosgrove D, Harvey C. Clinical use of microbubbles for imaging and therapy. Med Biol Eng Comput 2009; 47: 813-26.
4. Schutt EG, Klein DH, Mattrey RM, Riess JG. Injectable microbubbles as contrast agents for diagnostic ultrasound imaging: The key role of perfluorochemicals. Angew Chem Int Ed 2003; 42: 3218-35.
5. Cosgrove D. Ultrasound contrast agents: an overview. Eur J Radio 2006; 60: 324-30.
6. V. Response of contrast agents to ultrasound. Adv Drug Deliv Rev 2008; 60: 1117-36.
7. Ferrara K, Pollard R, Borden M. Ultrasound micro-bubble contrast agents: fundamentals and and application to gene and drug delivery. Annu Rev Biomed Eng 2007; 9: 415-47.
8. Qin S, Caskey CF, Ferrara KW. Ultrasound contrast microbubbles in imaging and therapy: physical principles and engineering. Phys Med Biol 2009; 54: R27-57.
9. Chen, WS, Matula TJ, Brayman AA, Crum LA. A comparison of the fragmentation thresholds and inertial cavitation doses of different ultrasound contrast agents. J Acoust Soc Am 2003; 113: 643-51.
10. Postema MAB. Medical Bubbles. Veenendaal: Universal Press 2004.
11. Bloch SH, Wan M, Dayton PA, Ferrara KW. Optical observation of lipid- and polymer-shelled ultrasound microbubble contrast agents. Appl Phys Lett 2004; 84: 631-3.
12. de Jong N, Hoff L, Skotland T, Bom N. Absorption and scatter of encapsulated gas filled microspheres: theoretical considerations and some measurements. Ultrasonics 1992; 30: 95-103.
13. Dalecki D.WFUMB safety symposium on echo-contrast agents: Bioeffects of ultrasound contrast agents in vivo. Ultrasound Med Biol 2007; 33: 205-13.
14. ter Haar G. Safety and bio-effects of ultrasound contrast agents. Med Biol Eng Comput 2009; 47: 893-900.
15. Ward M, Wu JR, Chiu JF. Ultrasound-induced cell lysis and sonoporation enhanced by contrast agents. J Acoust Soc Am 1999; 105: 2951-57.
16. Skyba DM, Price RJ, Linka AZ, Skalak TC, Kaul S. Direct in vivo visualization of intravascular destruction of microbubbles by ultrasound and its local effects on tissue. Circulation 1998; 98: 290-3.
17. Pitt WG, Husseini GA, Staples BJ. Ultrasonic drug delivery-a general review. Expert Opin Drug Deliv 2004; 1: 37-56.
18. Chen H, Kreider W, Brayman AA, Bailey MR, Matula TJ. Bood Vessel Deformations on Microsecond Time Scales by Ultrasonic Cavitation. Phys Rev Lett 2011; 106: 034301-1- 034301-4.
19. Stieger SM, Caskev CF, Adamson RH, et al. Enhancement of vascular permeability with low-frequency contrastenhanced ultrasound in the chorioallantoic membrane model. Radiology 2007; 243: 112-21.
20. Van Wamel A, Bouakaz A, Versluis M, De Jong N. Micromanipu-lation of endothelial cells: Ultrasound-microbubble-cell interaction. Ultrasound Med Biol 2004; 30: 1255-8.
21. Dalecki D, Child SZ, Raeman CH, Xing CC, Gracewski S, Car-stensen EL. Bioeffects of positive and negative acoustic pressures in mice infused with microbubbles Ultrasound Med Biol 2000; 26: 1327-32
22. Kaufmann BA, Lindner JR. Molecular imaging with targeted contrast ultrasound. Curr Opin Biotechnol 2007; 18: 11-6.
23. Schneider M. Molecular imaging and ultrasound- assisted drug delivery. J Endourol 2008; 22: 795-801.
24. Leong-Poi H, Christiansen J, Klibanov AL, Kaul S, Lindner JR. Noninvasive assessment of angiogenesis by ultrasound and micro-bubbles targeted to alpha(v)-integrins. Circulation, 2003; 107: 455-60.
25. Hamilton AJ, Huang, SL, Warnick D. Intravascular ultrasound molecular imaging of atheroma components in vivo. J Am Coll Cardiol 2004; 43: 453-60.
26. Epstein PS, Plesset MS. On the stability of gas bubbles in liquid-gas solutions. J Chem Phys 1950; 18: 1505-9.
27. Dressaire E, Bee R, Bell DC, Lips A, Stone HA. Interfacial polygonal nanopatterning of stable microbubbles. Science 2008; 320: 1198-1201.
28. Duncan R, Vicent MJ, Greco F, Nicholson R I. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer. 2005; 12: S189-99.
29. Grinstaff MW, Suslick KS. Proteinaceous microbubbles: synthesis of an echo contrast agent. Proc Natl Acad Sci USA 1991; 88: 7708-10.
30. Suslick KS, Grinstaff MW. Protein Microencapsulation of Nonaqueous Liquids. J Am Chem Soc 1990; 112: 7807-09.
31. Christiansen C, Kryvi H, Sontum PC, Skotland T. Physical and biochemical characterization of Albunex, a new ultrasound contrast agent consisting of air-filled albumin microspheres suspended in a solution of human albumin. Biotechnol Appl Biochem 1994; 19: 307-20.
32. Kamaev PP, Hutcheson JD, Wilson ML, Prausnitz MR. Quantification of optison bubble size and lifetime during sonication dominant role of secondary cavitation bubbles causing acoustic bioeffects. J Acoust Soc Am 2004;115: 1818-25.
33. Walday P, Tolleshaug H, Gjoen T, et al. Biodistributions of air-filled albumin microspheres in rats and pigs. Biochem J 1994; 299: 437-43.
34. Cavalieri F, Ashokkumar M, Grieser F, Caruso F. Ultrasonic synthesis of stable functional lysozyme microbubbles. Langmuir, 2008; 24: 10078-83.
35. Cunningham EE, Proctor VA, Goetsch SJ. Egg-white lysozyme as a food preservative: an overview. Worlds Poult Sci J 1991; 47: 141-63.
36. Zhou M, Cavalieri F and Ashokkumar M. Tailoring the properties of ultrasonically synthesised microbubbles. Soft Matter 2011; 7: 623-30.
37. [Melino S, Zhou M, Tortora M, Paci M, Cavalieri F, Ashokkumar M. Molecular properties of lysozyme-microbubbles: towards the protein and nucleic acid delivery. 2011, Submitted to Nucleic Acids.
38. Kipshidze NN, Porter TR, Dangas G. Novel site-specific systemic delivery of Rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in a porcine coronary restenosis model. Catheter Cardiovasc Interv 2005; 64: 389-94.
39. Zhenyu G, Xiaonan Z, Shaowei N, Zhiguo S, Hai-Meng Z. Con-formational changes of lysozyme refolding intermediates and implications for aggregation and renaturation. Int Biochem Cell Biol 2004; 36: 795-805.
40. Sunde M, Blake C. The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv Protein Chem 1997; 50: 123-59.
41. Hoff L. Acoustic Characterization of Contrast Agents for Medical Ultrasound Imaging. Dordrecht: Kluwer 2001.
42. Borden MA, Kruse D, Caskey C, Zhao S, Dayton P, Ferrara K. Influence of lipid shell physicochemical properties on ultrasound-induced microbubble destruction. IEEE Trans Ultrason Ferroelectr Freq Control 2005; 52: 1992-2002.
43. Dayton PA, Morgan KE, Klibanov AL, Brandenburger GH, Ferrara KW. Optical and acoustical observations of the effects of ultrasound on contrast agents. IEEE Trans. Ultrason Ferroelectr. Freq Control 1999; 46: 220-32.
44. Morgan KE, Allen JS, Dayton PA, Chomas JE, Klibanov AL, Ferrara KW. Experimental and theoretical evaluation of microbub-ble behavior: effect of transmitted phase and bubble size. IEEE Trans. Ultrason Ferroelectr Freq Control 2000; 47: 1494-509.
45. Klibanov A. L. Ligand-carrying gas-filled microbubbles: Ultrasound contrast agents for targeted molecular imaging. Bioconjug Chem 2005; 16: 9-17.
46. Borden MA, Zhang H, Gillies RJ, Dayton PA, Ferrara KW. A stimulus responsive contrast agent for ultrasound molecular imaging. Biomaterials 2008; 29: 597-606.
47. Ferrara KW, Borden MA, Zhang H. Lipid-shelled vehicles: engineering for ultrasound molecular imaging and drug delivery. Acc Chem Res 2009; 42: 881-92.
48. Hernot S, Klibanov AL. Microbubbles in ultrasound-triggered drug and gene therapy. Adv Drug Deliv Rev 2008; 60: 1153-66.
49. Transfection of plasmid DNA in cardiac and skeletal muscle with ultrasound and intravenous cationic microbubble vehicles. J Am Coll Cardiol 2002; 39: 361A.
50. Lentacker I, De Geest BG, Vandenbroucke RE, et al. Ultrasound-responsive polymer-coated microbubbles that bind and protect DNA. Langmuir 2006; 22: 7273-8.
51. Cui WJ, Bei JZ, Wang SG, et al. Preparation and Evaluation of Poly(L-lactide-co-glycolide) (PLGA) Microbubbles as a Contrast Agent for Myocardial Contrast Echocardiography. J of Biomed Mat Res Pt B: App Biomat 2005; 73B: 171-8.
52. Narayan P, Wheatley MA. Preparation and characterization of hollow microcapsules for use as ultrasound contrast agents. Polym Eng Sci 1999; 39: 2242-55.
53. Cavalieri F, El Hamassi A, Chiessi E, Paradossi G. Stable polymeric microballoons as multifunctional device for biomedical uses: synthesis and characterization. Langmuir 2005; 21: 8758-64.
54. Tzvetkov G, Graf B, Fernandes P, et al. In situ characterization of gas-filled microballoons using soft X-ray microspectroscopy. Soft Matter 2008; 4: 510-4.
55. Wheatley MA, Lathia JD, Oum KL. Polymeric ultrasound contrast agents targeted to integrins: importance of process methods and surface density of ligands. Biomacromol, 2006; 8: 516-22.
56. Rychak JJ, Lindner JR, Ley K, et al. Deformable gas-filled micro-bubbles targeted to P-selectin. J Control Release 2006; 114: 288-99.
57. Duncan R. In: D. Budman, H. Calvert, E. Rowinsky (Eds.), Handbook of anticancer drug development. Lippincott: Williams & Wil-kins. 2003; 239-60.
58. Lloyd JB. Lysosome membrane permeability: implications for drug delivery. Adv Drug Deliv Rev 2000; 41:189-200.
59. Wischke C, Schwendeman SP. Principles of encapsulating hydro-phobic drugs in PLA/PLGA microparticles. Int J Pharm 2008; 364: 298-327.
60. El-Sherif DM, Lathia J, Ngocyen L, Wheatley MA. Ultrasound degradation of novel polymer contrast agents. J Biomat Mater Res, 2004; 68A(1): 71-78.
61. Sohn M, Al-Ghananeem A, DeLuca P. P Int. Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects mansour. J Mol Sci 2010: 11; 3298-322.
62. Shomura Y, Tanigawa N, Shibutani M, et al. Water-soluble poly-vinyl alcohol microspheres for temporary embolization: development and in vivo characteristics in a pig kidney model. J Vasc Inter Rad 2011; 2: 212-9.
63. Cavalieri F, Zhou M, Caruso F, Ashokkumar M. One-pot ultrasonic synthesis of multifunctional microbubbles and microcapsules using synthetic thiolated macromolecules. Chem Comm. 2011; 47: 4096-98.
64. Rapoport NY, Kennedy AM, Shea JE, Scaife CL, Nam KHJ. Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles. J Control Release 2009; 138: 268-76.
65. Moghimi SM, Hamad I. Factors controlling pharmacokinetics of intravenously injected nanoparticulate systems. Biotechnology: Pharmaceutical Aspects 2009; X: 267-82.
66. Tartis MS, Kruse DE, Zheng HR, et al. Dynamic micro PET imaging of ultrasound contrast agents and lipid delivery. J Control Rel 2008; 131: 160-6.
67. Hoff L, Sontum PC, Hovem JM. Oscillation of polymeric micro-bubbles: Effect of the encapsulating shell. J AcoustSocAm 2000; 107: 2272-80.
68. Sirsi S, Feshitan J, Kwan J, Homma S, Borden M. Effect of micro-bubbles size on fondumental mode high frequency ultrasound imaging mice. Ultrasound Med Biol 2010; 36: 935-48.
69. Park JI, Tumarkin E, Kumacheva E. Small, stable, and monodis-persed bubbles encapsulated with biopolymers. Macromol Rapid Commun 2010; 31: 222-7.
70. Cavalieri F, Zhou M, Ashokkumar M. The design of multifunctional microbubbles for ultrasound image-guided cancer therapy. Curr Top Med Chem 2010; 12: 1198-210.
71. Bloch SH, Wan M, Dayton PA, Ferrara KW. Optical observation of lipid- and polymer-shelled ultrasound microbubble contrast agents. Appl Phys Lett 2004; 84: 631-3.
72. Li WW. Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad Radiol 2000; 7: 800-11.
73. Pasqualini R, Arap W, McDonald DM. Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med 2002; 8: 563-71.
74. Wickline SA, Lanza GM. Molecular imaging, targeted therapeutics and nanoscience. J Cell Biochem Suppl. 2002; 39: 90-7.
75. Wheatley MA, Lewandowski. Nano-ized ultrasound contrast agent: salting-out methodJ. Molecular Imaging 2010; 9: 96-107.
76. Dayton P, Klibanov A, Brandenburger G, Ferrara K. Acoustic radiation force in vivo: a mechanism to assist the targeting of mi-crobubbles. Ultrasound Med Biol 1999; 25: 1195-201.
77. Kairemo K, Erba P, Bergström K, Pauwels EKJ. Nanoparticles in Cancer. Current Radiopharmaceuticals 2008; 1: 30-36.
78. Park JI, Jagadeesan D, Williams R, et al. Microbubbles loaded with nanoparticles: a route to multiple imaging modalities ACS Nano 2010; 4: 6579-86.
79. [Seo M, Gorelikov I, Williams R, Matsuura N. Microfluidic assembly of monodisperse, nanoparticle-incorporated perfluorocarbon microbubbles for medical imaging and therapy. Langmuir 2010; 26: 13855-60.
80. Yang F, Zhang M, He W, et al. Controlled release of Fe3O4 nanoparticles in encapsulated microbubbles to tumor cells via sonoporation and associated cellular bioeffects. Small 2011; 7: 902-10.
81. Yang F, Li Y, Chen Z, et al. Superparamagnetic iron oxide nanoparticle-embedded encapsulated microbubbles as dual contrast agents of magnetic resonance and ultrasound imaging. Biomaterials 2009; 30: 3882-90.
82. Stride E. Physical principles of microbubbles for ultrasound imaging and therapy. Cerebrovasc Dis 2009; 27: 1-13.
83. Stride E, Pancholi K, Edirisinghe MJ, Samarasinghe S. Increasing the nonlinear character of microbubble oscillations at low acoustic pressures. J R Soc Interface 2008; 5: 807-11.
84. Lentacker I, Geers B, Demeester J, De Smedt SC, Sanders NN. Design and evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin delivery: cytotoxicity and mechanisms involved molecular therapy 2010; 18: 101-8.
85. Geers B, Lentacker I, Sanders NN, Demeester J, Meairs S, De Smedt SC. Self-assembled liposome-loaded microbubbles: The missing link for safe and efficient ultrasound triggered drug-delivery. J Control Rel 2011; 152: 249-56.
86. Baselga J. Clinical trials of single-agent trastuzumab (Herceptin). Semin Oncol 2000; 27: 20-6.
87. Chisti MA, Yang DSJanus C, et al. Early-onset amyloid deposition and cognitive deficits in tansgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001; 276: 21562-70.
88. Klyubin I, Walsh D M, Lemere CA. Amyloid beta proteinimmuno-therapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005; 11: 556-61.
89. Hynynen K. Ultrasound for drug and gene delivery to the brain. Adv Drug Deliv Rev 2008; 60: 1209-17.
90. Clement GT, Hynynen K. A non-invasive method for focusing ultrasound through the human skull. Phys Med Biol 2002; 47: 1219-36.
91. Aubry JF, Tanter M, Pernot M, Thomas JL, Fink M. Experimental demonstration of noninvasive transskull adaptive focusing based on prior computed tomography scans. J Acoust Soc Am 2003; 113:84-93.
92. Liu Radiology. Blood-Brain Barrier Disruption with Focused Ultrasound Enhances Delivery of Chemotherapeutic Drugs for Glioblastoma Treatment. Radiology, 2010: 255; 415-25.
93. Hynynen K, McDannold N, Vykhodtseva N, et al. Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neuro-surg 2006: 105; 445-54.
94. Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N. Local and reversible blood-brain barrier disruption by noninva-sive focused ultrasound at frequencies suitable for trans-skull soni-cations. NeuroImage 2005; 24: 12-20.
95. Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Biochem Biophys Res Commun. 2006: 340; 1085-90.
96. Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci USA 2006; 103: 11719-23.
97. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Noninva-sive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 2001; 220: 640-6.
98. McDannold N, Vykhodtseva N, Hynynen K. Targeted disruption of the blood-brain barrier with focused ultrasound: association with cavitation activity. Phys Med Biol 2006; 51: 793-807.
99. Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, Hynynen K. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer 2007; 121: 901-7.
100. von Holst H, Knochenhauer E, Blomgren H, et al. Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas. Acta Neurochir 1990; 104:13-6.
101. Hynynen K, Mcdannold N, Vykhodtseva N, et al. Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neuro-surg 2006; 105:445-54.
102. Hall-Stoodley L, Stoodley P. Evolving concepts in biofilm infections. Cell Microbiol 2009; 11: 1034-43.
103. Oggioni MR, Trappetti C, Kadioglu A, et al. Switch from plank-tonic to sessile life: a major event in pneumococcal pathogenesis. Mol Microbiol 2006; 61: 1196-210.
104. Baldassarri L, Creti R, Recchia S. Therapeutic failures of antibiotics used to treat macrolide-susceptible Streptococcus pyogenes infections may be due to biofilm formation. J Clin Microbiol 2006; 44: 2721-7.
105. Baldassarri L, Bertuccini L, Ammendolia MG, Arciola CR, Mon-tanaro L. Effect of iron limitation on slime production by Staphylo-coccus aureus. Eur J Clin Microbiol Infect Dis. 2001; 20: 343-5.